share_log

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts

Benzinga ·  Jun 27 21:00

6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings32100
Last 30D00100
1M Ago10000
2M Ago11000
3M Ago11000

The 12-month price targets, analyzed by analysts, offer insights with an average target of $65.0, a high estimate of $82.00, and a low estimate of $53.00. A 0.61% drop is evident in the current average compared to the previous average price target of $65.40.

price target chart

Breaking Down Analyst Ratings: A Detailed Examination

The analysis of recent analyst actions...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment